16. An anti-FcRn antibody according to any one of claims 1 to 11, wherein the antibody is a full length antibody.
17. An anti-FcRn antibody according to claim 16 wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.
18. An anti-FcRn antibody according to claim 16 or claim 17 having a heavy chain comprising the sequence given in SEQ ID NO:72 or SEQ ID NO:87 or SEQ ID NO:43 and a light chain comprising the sequence given in SEQ ID NO:22.
19. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 11 wherein the antibody or binding fragment thereof is a Fab-dsFv having a heavy chain comprising the sequence given in SEQ ID NO:50 and a light chain comprising the sequence given in SEQ ID NO:46 or SEQ ID NO:78.
20. An anti-FcRn antibody or binding fragment thereof having a binding affinity for human FcRn of 100pM or less.
21. An anti-FcRn antibody or binding fragment thereof according to claim 20 wherein the binding affinity for human FcRn is 100pM or less when measured at pH6 and at pH7.4.
22. An anti-FcRn antibody or binding fragment thereof which binds to the same epitope of human FcRn as the antibody of claim 10.
23. An anti-FcRn antibody or binding fragment thereof which binds an epitope of human FcRn which comprises at least one amino acid selected from the group consisting of residues V105, P106, T107, A108 and K109 of SEQ ID NO:94 and at least one residue selected from the group consisting of P100, E115, E116, F117, M118, N119, F120, D121, L122, K123, Q124, G128, G129, D130, W131, P132 and E133 of SEQ ID NO:94.
24. An anti-FcRn antibody or binding fragment thereof which cross-blocks the binding of the antibody of claim 10 to human FcRn or is cross-blocked from binding human FcRn by the antibody of claim 10.
25. An anti-FcRn antibody or binding fragment thereof according to any one of claims 20 to 24 which is humanized or fully human.
26. An anti-FcRn antibody or binding fragment thereof according to any one of claims 22 to 25 which has a binding affinity for human FcRn of 100pM or less.
27. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 26 which binds human FcRn.
28. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 27 which blocks binding of human IgG to human FcRn.
29. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 28 which does not bind β2 microglobulin.
30. ~~An assay for testing the ability of a test molecule such as an antibody molecule to block human FcRn activity and in particular the ability of human FcRn to recycle IgG, wherein the method comprises the steps of:~~
    a. ~~coating onto a surface non-human mammalian cells recombinantly expressing human FcRn alpha chain and human β2 microglobulin (β2M),~~

b. ~~contacting the cells under mildly acidic conditions such as about pH5.9 with a test antibody molecule and an IgG to be recycled by the cell for a period of time sufficient to allow binding of both the test antibody molecule and IgG to FcRn,~~

c. ~~washing with a slightly acidic buffer, and~~

d. ~~detecting the amount of IgG internalised and/or recycled by the cells.~~

31. ~~The assay according to claim 30 wherein the the test antibody molecule is added before the IgG to be recycled and incubated for a period of time sufficient to allow binding of the test antibody molecule to FcRn before addition of the IgG to be recycled.~~

~~32.~~30. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to 29.

~~33.~~31. A cloning or expression vector comprising one or more DNA sequences according to claim ~~32~~30.

~~34.~~32. A vector according to claim ~~33~~31, wherein the vector comprises (i) the sequence given in SEQ ID NO:37 and the sequence given in SEQ ID NO:23 or (ii) the sequence given in SEQ ID NO:80 and the sequence given in SEQ ID NO:79 or (iii) the sequence given in SEQ ID NO:93 and the sequence given in SEQ ID NO:91.

~~35.~~33. A host cell comprising one or more cloning or expression vectors according to claim ~~33~~ 31 or claim ~~34~~32.

~~36.~~34. A process for the production of an antibody having binding specificity for human FcRn, comprising culturing the host cell of claim ~~35~~ 33 and isolating the antibody.

~~37.~~35. A pharmaceutical composition comprising an anti-FcRn antibody or binding fragment thereof as defined in any one of claims 1 to 29 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

~~38.~~36. A pharmaceutical composition according to claim ~~37~~35, additionally comprising other active ingredients.

~~39.~~37. An antibody or binding fragment thereof as defined one in any one of claims 1 to 29 or a composition as defined in claim ~~37~~ 35 or ~~38~~ 36 for use in therapy.

~~40.~~38. An antibody or binding fragment thereof as defined in any one of claims 1 to 29 or a composition as defined in claim ~~37~~ 35 or ~~38~~36, for use in the treatment of an autoimmune disease, such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, and thrombotic thrombocytopenic purpura.

41. ~~A method of treating a patient comprising administering a therapeutically effective amount of an antibody or binding fragment thereof as defined in any one of claims 1 to 29 or a composition as defined in claim 37 or claim 38.~~

42. ~~A method according to claim 41, wherein the treatment is for an autoimmune disease such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, and thrombotic thrombocytopenic purpura.~~